Journal Article (Review Article)

DKFZ-2025-01656

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Clinical perspective and treatment of immune-related colitis after cancer immunotherapy.

Braun, L. M.DKFZ* ; Lu, Y. ; Zeiser, R.DKFZ*

2025
Elsevier Amsterdam

This record in other databases:  

Please use a persistent id in citations: doi:10.1016/j.trecan.2025.07.005

Abstract: Targeting negative regulators of immunity with immune-checkpoint inhibitors (ICIs) has led to significant survival benefit in patients with various cancer entities. ICI therapy disrupts mechanisms of immune tolerance, which induces inflammatory toxicities in different target organs, summarized as immune-related adverse events (irAEs) in some patients. ICI-colitis relies on the activation of intestinal tissue-resident memory T cells (TRM cells) and is one of the most frequently observed immune-related toxicities; it can be fatal if untreated. The disease is associated with highly cytotoxic intestinal T cells and inflammatory myeloid activation. Current clinical management relies on broad immunosuppression, potentially reducing antitumor immunity. Ideal future therapies for irAEs will uncouple immunosuppressive activities in the inflamed target organ and the tumor microenvironment.

Keyword(s): anticancer immunity ; cancer immunotherapy ; checkpoint blockade ; colitis ; immune-checkpoint inhibitor ; immune-related adverse events ; immune-related colitis ; inflammatory toxicities

Note: epub

---

Contributing Institute(s):

1. DKTK Koordinierungsstelle Freiburg (FR01)

Research Program(s):

1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2025

---

Database coverage:
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; IF >= 15 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---